The prevalence of PD-L1 expression in the population of patients with NSCLC ranges from 24% to 60%, even with a cutoff for positivity set at 5% [8], and it is estimated that 25 to 35% of advanced NSCLC cases test positive for PD-L1 in at least 50% of TCs. Here, CD274 is linked to non-small cell lung carcinoma.